Originally founded as an immunohistochemistry (IHC) services provider, LifeSpan Biosciences has evolved to offer a broad range of antibodies, kits, proteins and other biological reagents to nclude proprietary, value-added and third-party products. LifeSpan BioSciences employs molecular pathology, microarray and bioinformatics technology to identify and validate targets for drug discovery and target validation. LifeSpan also builds human expression databases for select pharmaceutical and biotechnology customers. As part of its growth strategy, the Company had planned to continue expanding its catalog of high-quality reagents, both through internal research and development and a targeted acquisition strategy. In September 2019, it was announced that Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, hadpartnered with management to acquire Seattle-based LifeSpan BioSciences, Inc., (LSBio). From the firm's highly specific niche in its industry and good reputation, LSBioâs new owners plan to expand upon its capabilities to provide the vital materials necessary for fueling important scientific research
